Abstract
A 20-month-old male with fulminant infectious mononucleosis and the X-linked lymphoproliferative syndrome (XLP) was studied. Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA) and EBV DNA were detected in various tissues. Despite a combined treatment with acyclovir, immunoglobulin, and methylprednisolone, the patient deteriorated rapidly. Following treatment with recombinant interferon-gamma (IFN-γ), defervescence occurred and circulating EBNA-positive cells markedly decreased. IFN-γ prior to treatment ranged from 10.8 to 24.5 U/ml in the patient's serum and increased linearly post exogenous IFN-γ treatment. His natural killer (NK)-cell activity remained in the normal range throughout his illness but autologous EBV-infected cells were not killedin vitro by his peripheral blood lymphocytes (PBL). These results suggest that patients with the fatal infectious mononucleosis phenotype of XLP may produce endogenous IFN-γ. Defective cytotoxic T cells against EBV-infected cells seem to be responsible for the fulminant infectious mononucleosis in this patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Epstein MA, Achong BG: Introductory considerations.In The Epstein-Barr virus: Recent advances, MA Epstein, BG Achong (eds), Bedford Square, London, William Heinemann Medical Books, 1986, pp 1–11
Okano M, Thiele GM, Davis JR, Grierson HL, Purtilo DT: Epstein-Barr virus and human diseases: Recent advances in diagnosis. Clin Microbiol Rev 1:300–312, 1988
Grierson H, Purtilo DT: Epstein-Barr virus infections in males and the X-linked lymphoproliferative syndrome. Ann Intern Med 106:538–545, 1987
Markin RS, Linder J, Zuerlin K, Mroczek E, Grierson HL, Brichacek B, Purtilo DT: Hepatitis in fatal infectious mononucleosis. Gastroenterology 93:1210–1217, 1987
Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL: Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplant 39:461–472, 1985
Sullivan JL, Medveczky P, Forman SJ, Baker SM, Monroe JE, Mulder C: Epstein-Barr virus-induced lymphoproliferation. Implications for antiviral chemotherapy. N Engl J Med 311:1163–1167, 1985
Falletta JM, Fernbach DJ, Singer DB, South MA, Landing BH, Health Jr CW Shore NA, Barrett FF: A fatal X-linked recessive reticuloendothelial syndrome with hyperglobulinemia. X-linked recessive reticuloendotheliosis. J Pediat 183:549–556, 1973
Kurzrock R, Quesada JR, Talpaz M, Hersh EM, Reuben J, Sherwin SA, Gutterman JU: Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 4:1101–1109, 1986
Pross HF, Bines MG, Rubin P, Shragge P, Patterson MS: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantification of natural killer cell activity. J Clin Immunol 1:51–63, 1981
Matthews DE, Farewell V: Using and Understanding Medical Statistics. New York, Karger Basel, 1985
Pagano JS, Datta AK: Perspectives on interactions of acyclovir with Epstein-Barr and other herpesviruses. Am J Med 73:18–26, 1982
Andersson J, Britton S, Ernberg I, Andersson U, Henle W, Skoldenberg B, Tisell A: Effect of acyclovir on infectious mononucleosis: A double blind, placebo controlled study. J Infect Dis 153:283–290, 1986
Sullivan JL, Byron KS, Brewster FE, Baker SM, Ochs HD: X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency. J Clin Invest 71:1765–1778, 1983
Purtilo DT, Cassel CK, Yang JPS, Harper R, Stephenson SR, Landing BH, Vawter GF: X-linked recessive progressive combined variable immunodeficiency. Lancet 1:935–941, 1975
Murray HW: Interferon-gamma, the activated macrophages, and host defense against microbial challenge. Ann Intern Med 108:595–608, 1988
Matricardi PM, Capobianchi MR, Paganelli R, Facchini J, Sirianni MC, Seminara R, Dianzani F, Aiuti F: Interferon production in primary immunodeficiencies. J Clin Immunol 4:388–394, 1984
Cheeseman SH, Henle W, Rubin RH, Tolkoff NE, Cosimi B, Cantel K, Winkle S, Herrin JT, Black PH, Russel PS, Hirsch NS: Epstein-Barr virus infection in renal transplant recipients: Effects of antithymocyte globulin and interferon. Ann Intern Med 93:39–42, 1980
Shapiro RS, Chauvenet A, McGuire W, Pearson A, Craft AW, McGlave P, Filipovich A: Treatment of B-cell lymphoproliferative disorders with interferon alpha and intravenous gammaglobulin. N Engl J Med 318:1334, 1988
Connors JM, Andiman WA, Howarth CB, Liu E, Merigan TC, Savage ME, Jacobs C: Treatment of nasopharyngeal carcinoma with human leukocyte interferon. J Clin Oncol 3:813–817, 1985
Treuner J, Niethammer D, Dannecker G, Hagmann R, Neef V, Hofschneider PH: Successful treatment of nasopharyngeal carcinoma with interferon. Lancet 1:817–818, 1980
Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB: Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation. J Exp Med 157:173–188, 1983
Blanche S, Le Deist F, Veber F, Lenoir G, Fischer AM, Brochier J, Boucheix C, Delaage M, Griscelli C, Fisher A: Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies: Two cases after HLA-mismatched bone marrow transplantation. Ann Intern Med 108:199–203, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okano, M., Thiele, G.M., Kobayashi, R.H. et al. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection. J Clin Immunol 9, 48–54 (1989). https://doi.org/10.1007/BF00917127
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00917127